Merck is going to cause a global catastrophe with its Molnupiravir. Merck intends to produce and ship 30 million courses of this poison by the end of 2022, and to earn $5B to $6B from them. And there might be more, “depending on how the pandemic plays out” – in the real words of Merck’s CFO.